Abstract:Background: But so far there is no proven pharmacological treatment for Idiopathic pulmonary fibrosis (IPF). As trials investigating different agents with different mechanisms of actions are going on, encouraging results have led to the licensing of the first IPF-specific drug, Pirfenidone. Objective: To assess the proportion of IPF among interstitial lung disease patients and to assess their treatment response to Pirfenidone. Material and methods: All consecutive patients attending the outpatient department from 1st January 2012 to 30th June 2012 with a proven diagnosis of Interstitial lung Disease (ILD) were included in this longitudinal cohort study. Out of the total ILDs, patients with IPF were identified. The disease, its natural course, available treatment options and the risks and benefits of drugs were discussed with each IPF patient along with their family members. After obtaining their consent, we started 23 patients on a combination of Pirfenidone, N-acetyl cysteine (NAC) and proton pump inhibitors (PPI). Patients were followed up for 52 weeks. Pirfenidone was discontinued in one patient due to an adverse effect 1 month after onset of treatment. Anova test using SPSS software and independent T test was used to analyse the data. Results: During the study period 69 patients with ILD attended our OPD which included 24 IPF patients representing 34.8% and 23 of these patients received treatment with Pirfenidone, NAC and PPI. One patient discontinued Pirfenidone due to adverse effects. After 12 months, 8 patients had worsening of FVC ≥10%, the FVC of 7 patients remained stable, 8 patients could not repeat the tests and none of them had improvement. There was less than 15% decline in DLCO for 9 patients, 7 patients could not repeat the test and none improved. 8 patients had stable dyspnoea on exertion and 11 had worsening. Three patients died. Combining all the above parameters, only 4 patients had stable disease with the rest having no improvement. Conclusions: The present study does not show any significant beneficial effect for Pirfenidone. Only four patients remained stable which cannot be attributed to the effect of any particular management strategy.

Pirfenidone: A Promising Drug in Ocular Therapeutics

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

Pirfenidone as a Cornerstone in the Management of Fibrotic Interstitial Lung Diseases and Its Emerging Applications: A Comprehensive Review

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy

Use of pirfenidone in fibrotic interstitial lung diseases and beyond: a review

Pirfenidone as a novel cardiac protective treatment

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant

Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease

Pirfenidone release from ophthalmic implants – perspectives for a drug-eluting microstent for glaucoma therapy

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases

Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis

Pirfenidone for Diabetic Nephropathy

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice

Antifibrotic activities of pirfenidone in animal models

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study

The evolving pharmacotherapy of pulmonary fibrosis